Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Corvus Pharmaceuticals Inc CRVS

Healthcare Biotechnology
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, a selective, covalent inhibitor of ITK (interleukin 2 inducible T cell kinase) and is in a multi-center Phase 1/1b clinical trial in... see more

Recent & Breaking News (NDAQ:CRVS)

Corvus Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

GlobeNewswire March 10, 2017

Corvus Pharmaceuticals to Host R&D Day Highlighting the Role of the Adenosine Pathway in Immuno-Oncology

GlobeNewswire March 9, 2017

Corvus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference 2017

GlobeNewswire February 27, 2017

Corvus Pharmaceuticals Announces Expansion of Renal Cell Carcinoma Cohort in Ongoing Phase 1/1b Clinical Study of Lead Checkpoint Inhibitor CPI-444

GlobeNewswire January 10, 2017

Corvus Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference 2017

GlobeNewswire January 4, 2017

Corvus Pharmaceuticals Names Ian T. Clark, Former Genentech Chief Executive Officer, to Board of Directors

GlobeNewswire January 3, 2017

Corvus Pharmaceuticals Announces Preliminary Phase 1/1b Clinical Data with Lead Checkpoint Inhibitor CPI-444 Demonstrating Safety and Evidence of Anti-Tumor Activity as a Single Agent in Patients with Advanced Refractory Cancers

GlobeNewswire November 11, 2016

Corvus Pharmaceuticals Announces Third Quarter Financial Results and Provides Business Update

GlobeNewswire November 3, 2016

Corvus Pharmaceuticals to Present at SITC’s 31st Annual Meeting

GlobeNewswire November 2, 2016

Corvus Pharmaceuticals to Present at Credit Suisse 25th Annual Healthcare Conference

GlobeNewswire November 1, 2016

Corvus Pharmaceuticals Announces Biomarker Findings from Phase 1/1b Study of Lead Oral Checkpoint Inhibitor CPI-444 Presented at ESMO 2016 Congress

GlobeNewswire October 10, 2016

Corvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at ESMO 2016 Congress

GlobeNewswire October 4, 2016

Corvus Pharmaceuticals Announces Preclinical and Preliminary Clinical Biomarker Data of Lead Oral Checkpoint Inhibitor CPI-444 Presented at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

GlobeNewswire September 25, 2016

Corvus Pharmaceuticals to Present Data on Lead Oral Checkpoint Inhibitor CPI-444 at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

GlobeNewswire September 19, 2016

Corvus Pharmaceuticals Announces Second Quarter Financial Results and Provides Business Update

GlobeNewswire August 4, 2016

Corvus Pharmaceuticals to Present at Cantor Fitzgerald’s Second Annual Healthcare Conference on July 12

GlobeNewswire July 6, 2016

Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer

GlobeNewswire June 29, 2016

Corvus Pharmaceuticals’ Ian McCaffery, PhD to Present at Rational Combinations 360° June 23-24, New York

GlobeNewswire June 17, 2016

Corvus Pharmaceuticals Announces First Quarter 2016 Financial Results

GlobeNewswire May 5, 2016

Corvus Pharmaceuticals Announces Results of Preclinical Studies Demonstrating Enhanced Immune Responses and Anti-Tumor Activity with CPI-444, an Investigational Immuno-Oncology Therapy

GlobeNewswire April 19, 2016